Get the Stockscreener App
18.84
1.82%
-0.35
After Hours:
18.84
Relay Therapeutics Inc stock is traded at $18.84, with a volume of 10.06M.
It is down -1.82% in the last 24 hours and down -8.59% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
See More
Previous Close:
$19.19
Open:
$19.25
24h Volume:
10.06M
Relative Volume:
3.26
Market Cap:
$4.13B
Revenue:
$10.68M
Net Income/Loss:
$-272.71M
P/E Ratio:
-12.04
EPS:
-1.565
Net Cash Flow:
$-213.38M
1W Performance:
-0.16%
1M Performance:
-8.59%
6M Performance:
+89.73%
1Y Performance:
+314.07%
1-Day Range:
$18.68
$19.40
1-Week Range:
$18.62
$19.69
52-Week Range:
$4.32
$21.27
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
18.84 | 4.14B | 10.68M | -272.71M | -213.38M | -1.565 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-12-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Why Is RLAY Stock Rising Today? - Stocktwits
Relay Therapeutics CEO Sanjiv Patel sells 48,199 shares for $912,889.06 - Bitget
Relay Therapeutics (RLAY) Insider Sell: President, R&D Donald Be - GuruFocus
Relay Therapeutics R&D president sells $161,814 in stock By Investing.com - Investing.com South Africa
Relay Therapeutics R&D president sells $161,814 in stock - investing.com
Relay Therapeutics Insider Sold Shares Worth $912,889, According to a Recent SEC Filing - marketscreener.com
Relay Therapeutics (RLAY) R&D chief sells stock under 10b5-1 plan - Stock Titan
Relay Therapeutics (RLAY) CFO sells about $335K in stock under preset plan - Stock Titan
Relay Therapeutics (NASDAQ: RLAY) CEO sells shares under preset trading plan - Stock Titan
Relay Therapeutics at Wells Fargo conference: pipeline nears key tests By Investing.com - Investing.com Canada
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September - news.futunn.com
RLAY Stock Declines Pre-Market After $175M Offering — Despite Fresh Bullish Calls On Relay's Zovegalisib - Stocktwits
Relay Therapeutics CFO Sells 17,717 Shares for $350,000 - Yahoo Finance
Relay Therapeutics to Participate in Upcoming September Healthcare Conference Fireside Chats - Quiver Quantitative
Relay Therapeutics management will join two live online talks this month - Stock Titan
Relay Therapeutics (RLAY) Insider Peter Rahmer Sells 4,508 Shares - GuruFocus
Relay Therapeutics (RLAY) exec sells 4,508 shares under plan - Stock Titan
SoftBank Vision Fund Subsidiary Sells 6 Million Shares of Relay Therapeutics at $19.4 Each - Kalkine Media
Relay Therapeutics director SVF Pauling (Cayman) sells $116.4m By Investing.com - Investing.com Canada
Relay Therapeutics (NASDAQ: RLAY) 10% owner SoftBank sells 6M shares - Stock Titan
Relay Therapeutics (NASDAQ: RLAY) officer eyes another stock sale after June trade - Stock Titan
Relay Therapeutics (NASDAQ: RLAY) holder plans sale of up to 6M shares - Stock Titan
What is HC Wainwright's Estimate for RLAY FY2027 Earnings? - MarketBeat
RLAY Maintained by HC Wainwright & Co. -- Price Target Raised to $29 - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Relay Therapeutics price target to $29 By Investing.com - Investing.com Canada
Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE - MarketBeat
Relay Therapeutics (RLAY) Reported Q2 Results, Is The Premium P B Multiple Justified? - Yahoo Finance
Relay Therapeutics (RLAY) Stock May Be Fully Valued After A 7x Run - simplywall.st
Timothy G. Youngquist 2020 Irrevocable Trust Boosts Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Handelsbanken Fonder AB Buys New Shares in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics Insider Sold Shares Worth $979,886, According to a Recent SEC Filing - marketscreener.com
Relay Therapeutics (RLAY) CEO sells 48K shares in plan trade - Stock Titan
Relay Therapeutics (RLAY) CFO sells shares via preset trading plan - Stock Titan
Relay (RLAY) Earnings Metrics: EPS Does Not Reach the Reported Estimate in Latest Trading - Vinanet
Relay Therapeutics stock hits 52-week high at 20.83 USD By Investing.com - Investing.com Canada
Relay Therapeutics stock hits 52-week high at 20.83 USD - Investing.com
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - The Globe and Mail
Alphabet Inc. Makes New Investment in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week High Following Analyst Upgrade - MarketBeat
Persistent Asset Partners Ltd Makes New $1.32 Million Investment in Relay Therapeutics, Inc. $RLAY - MarketBeat
Elmind Capital, LP's Relay Therapeutics Inc(RLAY) Holding History - GuruFocus
Relay Therapeutics (RLAY) Slips 0.35% as Shares Trade Near Midpoint of Key RangeValue Area Low - vinanet.vn
Relay Therapeutics (NASDAQ:RLAY) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
PERCEPTIVE ADVISORS LLC Expands Relay Therapeutics Inc (RLAY) St - GuruFocus
Relay Therapeutics (RLAY): Commodore Capital group discloses 12M-share, 5.5% position - Stock Titan
J.P. Morgan Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $31 - Moomoo
RLAY Maintained by JP Morgan -- Price Target Raised to $31.00 - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year - Barchart.com
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Relay Therapeutics Inc Stock (RLAY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Catinazzo Thomas | Chief Financial Officer |
Sep 08 '26 |
Sale |
18.94 |
17,717 |
335,560 |
122,851 |
| Patel Sanjiv | President and CEO |
Sep 08 '26 |
Sale |
18.94 |
48,199 |
912,889 |
519,500 |
| Rahmer Peter | See remarks |
Aug 26 '26 |
Sale |
20.03 |
4,508 |
90,295 |
223,657 |
| SVF Pauling (Cayman) Ltd | 10% Owner |
Aug 25 '26 |
Sale |
19.40 |
6,000,000 |
116,400,000 |
21,904,963 |
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):